Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NN9924 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Trial part 1 | EXPERIMENTAL | - |
| Trial part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NN9924 (oral) | DRUG | Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation. |
| placebo | DRUG | Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels. |
| NN9924 (s.c.) | DRUG | As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit |
| NN9924 (i.v.) | DRUG | As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit. |
Inclusion Criteria: * Male subjects with good general health as judged by the Investigator * Body weight of 65.0-95.0 kg (both inclusive) * Body Mass Index (BMI) of 18.5-27.5 kg/m\^2 (both inclusive) Exclusion Criteria: * Known or suspected allergy to trial product or related products * Acute inf...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NN9924 is an investigational small molecule being developed for diabetes, including type 2 diabetes. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
NN9924 is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the New York Stock Exchange under the ticker NVO.
NN9924 is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational.
NN9924 has one completed Phase 1 trial, NCT01037582, which investigated the safety of NN9924 in healthy male subjects. The trial enrolled 155 participants and was conducted in the United Kingdom.
Yes, NN9924 has been studied in healthy volunteers. The completed Phase 1 trial, NCT01037582, enrolled healthy male subjects aged 18 years and older.